DOCSLIB.ORG

CELEBREX.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
CELEBREX.Pdf IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION • Inflammatory bowel disease (Crohn’s Disease or Pr ® Ulcerative Colitis) CELEBREX • Liver disease (active or severe) (Celecoxib) • Kidney disease (severe or worsening) • High potassium in the blood Read this information each time you refill your prescription in case new information has been added. CELEBREX is NOT recommended for use in patients This leaflet is a summary designed specifically for you to under 18 years of age since the safety and effectiveness read. It will NOT tell you everything about CELEBREX. of CELEBREX have NOT been established in these See your health care provider and pharmacist regularly and patients. ask them questions about your health and any medications you take. Patients who took a drug in the same class as CELEBREX after a type of heart surgery (coronary artery bypass grafting (CABG) were more likely to have heart attacks, ABOUT THIS MEDICATION strokes, blood clots in the leg(s) or lung(s), and infections or other complications than those who did NOT take that What the medication is used for: drug. Your health care provider has prescribed CELEBREX for you for one or more of the following medical conditions: What the medicinal ingredient is: Celecoxib • Osteoarthritis – relieve pain • Rheumatoid Arthritis – relieve joint pain and swelling What nonmedicinal ingredients are: • Ankylosing Spondylitis – relieve pain Croscarmellose sodium, Ferric oxide edible ink (E172) (200 • Sprains, After orthopaedic (bone and joint) surgery (NOT mg capsules), Gelatin, Indigotine edible ink (E132) (100 mg open heart surgery), dental extraction – to relieve short-term capsules), Lactose monohydrate, Magnesium stearate, pain (maximum use of 7 days) Povidone, Sodium lauryl sulphate, Titanium dioxide (E171) What it does: What dosage forms it comes in: CELEBREX (celecoxib), as a nonsteroidal anti-inflammatory Capsules, 100 mg and 200 mg drug (NSAID), can reduce the type of prostaglandins (chemicals), produced by your body which cause joint WARNINGS AND PRECAUTIONS swelling, redness and pain. At prescribed doses, CELEBREX does not affect the type of prostaglandins that helps maintain the protective layer of the stomach, and reduces the chances of Serious Warnings and Precautions bleeding from the stomach. If you have, or previously had, any of the following medical conditions, see your health care provider to CELEBREX, as a nonsteroidal anti-inflammatory drug discuss treatment options to consider before taking (NSAID), does NOT cure your illness or prevent it from CELEBREX: getting worse. CELEBREX can only relieve pain and reduce swelling as long as you continue to take it. • Heart Attack or Angina • Stroke or Mini-stroke When it should not be used: • Loss of Vision Do not take CELEBREX if you have any of the • Congestive Heart Failure following medical conditions: • Current Pregnancy (less than 28 weeks) • Heart bypass surgery (planning to have or recently • Ulcer or bleeding from the gut had) • Severe, uncontrolled heart failure Also consult your healthcare provider if you are • Allergy to celecoxib or any of the other ingredients in taking a dose of CELEBREX which is higher than CELEBREX 200mg per day or if you have been taking • Allergy to sulfonamide drugs CELEBREX regularly for over 18 months. Patients in this situation have an increased risk of a serious • Allergy to ASA (Acetylsalicylic Acid) or other NSAIDs cardiovascular side effect such as the ones described (Nonsteroidal Anti-Inflammatory Drugs) above. • Pregnancy of more than 28 weeks (in your third trimester) • Currently breastfeeding (or planning to breastfeed) BEFORE you use CELEBREX talk to your doctor or • Ulcer (active) pharmacist if you have any of the following: • Bleeding from the stomach or gut (active) • Disease of the heart or blood vessels (also called • Bleeding in the brain or other bleeding disorders cardiovascular disease, including uncontrolled high CELEBREX (celecoxib) – Product Monograph Page 54 of 57 IMPORTANT: PLEASE READ blood pressure, congestive heart failure, established INTERACTIONS WITH THIS MEDICATION ischemic heart disease, or peripheral arterial disease) • Risk factors for cardiovascular disease (see above) such as high blood pressure, abnormally high levels of fat Talk to your health care provider and pharmacist if you are (cholesterol, triglycerides) in your blood taking any other medication (prescription or non-prescription) such as any of the following (NOT a complete list): • Diabetes mellitus or on a low sugar diet • Atherosclerosis • Acetylsalicylic acid (ASA) or other NSAIDs (e.g. • Poor circulation to your extremities diclofenac, ibuprofen, indomethacin, ketorolac, • Smoker or ex-smoker meloxicam, naproxen) • Kidney disease or urine problems • Antacids or proton pump inhibitors (omeprazole) • Previous ulcer or bleeding from the stomach or gut • Antidepressants [Selective serotonine receptor uptake • Previous bleeding in the brain inhibitor (SSRIs) (e.g. citalopram, paroxetine, fluoxetine, • Bleeding problems sertraline)] • Family history of allergy to sulfonamide drugs • Blood pressure medications, such as ACE (angiotensin • Family history of allergy to NSAIDs, such as converting enzyme) inhibitors (e.g. enalapril, lisinopril, acetylsalicylic acid (ASA), celecoxib, diclofenac, perindopril, ramipril), ARBs (angiotensin II receptor diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, blockers) (e.g. candesartan, irbesartan, losartan, indomethacin, ketoprofen, ketorolac, mefenamic acid, valsartan), beta blockers (e.g. metoprolol) meloxicam, nabumetone, naproxen, oxaprozin, • Blood thinners (to prevent blood clots), such as warfarin, piroxicam, rofecoxib, sulindac, tenoxicam, tiaprofenic apixaban, rivaroxaban, dabigatran, ASA, clopidogrel acid, tolmetin, or valdecoxib (NOT a complete list) • Corticosteroids (including glucocorticoids) e.g. • Family history of asthma, nasal polyp, long-term prednisone swelling of the sinus (chronic sinusitis) or hives • Cyclosporin • Gastrointestinal problems (problems with your stomach • Digoxin and/or intestine) • Diuretics such as furosemide, hydrochlorothiazide • History of a severe drug hypersensitivity reaction • Fluconazole including skin problems • Lithium • Current pregnancy • Dextromethorphan (found in some cough medications) • Any other medical problem • Tacrolimus Fertility may be decreased. The use of CELEBREX is not Using CELEBREX with a blood thinner such as warfarin recommended in women who have difficulty conceiving. increases the risk of bleeding, which can be fatal, especially in older patients. Also, before taking this medication, tell your health care provider if you are planning to get pregnant. Your health care provider may prescribe low dose ASA (acetylsalicylic acid) as a blood thinner for the prevention of While taking this medication: having a heart attack or stroke while you are taking CELEBREX. Take only the amount of ASA prescribed by • tell any other doctor, dentist, pharmacist or other health your health care provider. You are more likely to upset or care professional that you see, that you are taking this damage your stomach if you take both CELEBREX and ASA medication, especially if you are planning to have heart than if you take CELEBREX alone. surgery; • do NOT drink alcoholic beverages while taking this medication because you would be more likely to develop PROPER USE OF THIS MEDICATION stomach problems; • If you have cardiovascular disease or risks for Dose: 18 years of age and older only cardiovascular disease, your doctor will periodically re- evaluate whether you should continue treatment with Medical Starting Maximum Maximum CELEBREX. Patients with these conditions should not Condition Dose Dose Duration of receive doses of CELEBREX higher than 200 mg per (per day) Treatment day. (days) Osteoarthritis 200 mg once 200 mg not If, at any time while taking CELEBREX you experience any (18 years of a day or 100 specified signs or symptoms of problems with your heart or blood age and older) mg twice a vessels such as chest pain, shortness of breath, weakness, or day slurring of speech, seek emergency medical treatment Rheumatoid 100 mg twice 400 mg not immediately. Arthritis a day specified CELEBREX (celecoxib) – Product Monograph Page 55 of 57 IMPORTANT: PLEASE READ (18 years of CELEBREX may cause you to become more sensitive to age and older) sunlight. Any exposure to sunlight or sunlamps may cause Ankylosing 200 mg once 200 mg not sunburn, skin blisters, skin rash, redness, itching or Spondylitis a day or 100 specified discolouration, or vision changes. If you have a reaction from (18 years of mg twice a the sun, check with your health care provider. age and older) day Pain 400 mg on 400 mg 7 days CELEBREX can cause abnormal laboratory test results. Your (18 years of first day, then doctor will decide when to perform laboratory tests and will age and older) 200 mg once interpret the results. They may check kidney function, liver a day function, amount of blood cells and other functions. Take CELEBREX only as directed by your health care Your doctor will decide when to measure the amount of your provider. Do NOT take more of it, do NOT take it more amniotic fluid during pregnancy. often and do NOT take it for a longer period of time than your health care provider recommended. If possible, you Check with your health care provider IMMEDIATELY if you should take the lowest dose of this medication for the develop chills, fever, muscle aches or pains, or other flu-like shortest time period.
Load more

Recommended publications
  • Native State Stabilization by Nsaids Inhibits Transthyretin Amyloidogenesis from the Most Common Familial Disease Variants
    Laboratory Investigation (2004) 84, 545–552 & 2004 USCAP, Inc All rights reserved 0023-6837/04 $25.00 www.laboratoryinvestigation.org Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants Sean R Miller, Yoshiki Sekijima and Jeffery W Kelly Department of Chemistry and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA Transthyretin (TTR) tetramer dissociation and misfolding affords a monomeric amyloidogenic intermediate that misassembles into aggregates including amyloid fibrils. Amyloidogenesis of wild-type (WT) TTR causes senile systemic amyloidosis (SSA), whereas fibril formation from one of the more than 80 TTR variants leads to familial amyloidosis, typically with earlier onset than SSA. Several nonsteroidal anti-inflammatory drugs (NSAIDs) stabilize the native tetramer, strongly inhibiting TTR amyloid fibril formation in vitro. Structure-based designed NSAID analogs are even more potent amyloid inhibitors. The effectiveness of several NSAIDs, including diclofenac, diflunisal, and flufenamic acid, as well as the diclofenac analog, 2–[(3,5-dichlorophenyl) amino] benzoic acid (inhibitor 1), has been demonstrated against WT TTR amyloidogenesis. Herein, the efficacy of these compounds at preventing acid-induced fibril formation and urea-induced tetramer dissociation of the most common disease-associated TTR variants (V30M, V122I, T60A, L58H, and I84S) was evaluated. Homotetramers of these variants were employed for the studies within, realizing that the tetramers in compound heterozygote patients are normally composed of a mixture of WT and variant subunits. The most common familial TTR variants were stabilized substantially by flufenamic acid and inhibitor 1, and to a lesser extent by diflunisal, against acid-mediated fibril formation and chaotrope denaturation, suggesting that this chemotherapeutic option is viable for patients with familial transthyretin amyloidosis.
    [Show full text]
  • Acute Renal Failure Associated with Diflunisal J. G. WHARTON D. 0
    Postgrad Med J: first published as 10.1136/pgmj.58.676.104 on 1 February 1982. Downloaded from Postgraduate Medical Journal (February 1982) 58, 104-105 Acute renal failure associated with diflunisal J. G. WHARTON D. 0. OLIVER B.Sc., M.R.C.P. F.R.C.P., F.R.A.C.P. M. S. DUNNILL F.R.C.P., F.R.C.Path. Renal Unit, Churchill Hospital, and Department of Pathology, John Radcliffe Hospital, Oxford Summary eosinophils 224 x 106/1; ESR 30 mm/hr; urea 305 The case of a 44-year-old man with acute oliguric mmol/l; creatinine 1651 ,Lmol/l; potassium 6-43 renal failure due to tubulo-interstitial nephritis after mmol/l; serum amylase 88 Somogyi units; urine 3 months' diflunisal is reported. The possible mecha- contained no casts; no red cells but 10 neutrophils, nisms are discussed. no eosinophils and no growth. Antistreptolysin 0 titre 50 i.u./ml; IgG 16-5 g/l; IgA 3-8 g/l; IgM 1.1 g/l antinuclear factor negative; C3 122 mg/dl, C4 54Protected by copyright. Introduction mg/dl; hepatitis B surface antigen negative; chest Diflunisal has been reported as causing acute radiograph, cardiomegaly plus congestion; intra- allergic interstitial nephritis (Chan et al., 1980) venous urogram with tomograms, no obstruction, resulting in acute oliguric renal failure. A case of poor nephrogram. A renal biopsy showed tubulo- acute renal failure due to tubulo-interstitial nephritis interstitial nephritis with no eosinophil infiltrate. after 3 months of diflunisal is reported here. Recently, Diflunisal had been stopped 2 days before admission phenylakalonic acids with analgesic and anti- to this renal unit.
    [Show full text]
  • Salicylate, Diflunisal and Their Metabolites Inhibit CBP/P300 and Exhibit Anticancer Activity
    RESEARCH ARTICLE Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity Kotaro Shirakawa1,2,3,4, Lan Wang5,6, Na Man5,6, Jasna Maksimoska7,8, Alexander W Sorum9, Hyung W Lim1,2, Intelly S Lee1,2, Tadahiro Shimazu1,2, John C Newman1,2, Sebastian Schro¨ der1,2, Melanie Ott1,2, Ronen Marmorstein7,8, Jordan Meier9, Stephen Nimer5,6, Eric Verdin1,2* 1Gladstone Institutes, University of California, San Francisco, United States; 2Department of Medicine, University of California, San Francisco, United States; 3Department of Hematology and Oncology, Kyoto University, Kyoto, Japan; 4Graduate School of Medicine, Kyoto University, Kyoto, Japan; 5University of Miami, Gables, United States; 6Sylvester Comprehensive Cancer Center, Miami, United States; 7Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States; 8Department of Biochemistry and Biophysics, Abramson Family Cancer Research Institute, Philadelphia, United States; 9Chemical Biology Laboratory, National Cancer Institute, Frederick, United States Abstract Salicylate and acetylsalicylic acid are potent and widely used anti-inflammatory drugs. They are thought to exert their therapeutic effects through multiple mechanisms, including the inhibition of cyclo-oxygenases, modulation of NF-kB activity, and direct activation of AMPK. However, the full spectrum of their activities is incompletely understood. Here we show that salicylate specifically inhibits CBP and p300 lysine acetyltransferase activity in vitro by direct *For correspondence: everdin@ competition with acetyl-Coenzyme A at the catalytic site. We used a chemical structure-similarity gladstone.ucsf.edu search to identify another anti-inflammatory drug, diflunisal, that inhibits p300 more potently than salicylate. At concentrations attainable in human plasma after oral administration, both salicylate Competing interests: The and diflunisal blocked the acetylation of lysine residues on histone and non-histone proteins in cells.
    [Show full text]
  • (Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
    TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs (Nsaids)* *See List of Prescription NSAID Nsaids Are Used to Treat Pain, Redness, Swelling, and Heat (Inflammation)
    Medication Guide Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)* *see list of prescription NSAID NSAIDs are used to treat pain, redness, swelling, and heat (inflammation). medicines at the end of this guide WHAT IS THE MOST IMPORTANT INFORMATION YOU SHOULD KNOW ABOUT NSAIDS? NSAIDs can increase the risk of kidney failure, gastrointestinal damage, heart attack or stroke. Heart Kidney Gastrointestinal Attack Damage Damage (GI) Never use right before or You should not take NSAIDs Beware of life-threatening after coronary bypass graft if you have one of these ulcers and bleeding that may ! (CABG) surgery. ! high-risk conditions: ! happen without warning. Your risk† of heart attack or • Kidney disease Your GI risk increases with: stroke increases if: • Diabetes • Taking medicines called corticosteroids • You have heart disease • High blood pressure and anticoagulants • Even with short-term use • You take water pills or pills with • Old age or having poor health † • Smoking and drinking alcohol low dose aspirin does not pose this risk names that end in ‘pril’ or ‘sartan’ Your health risks increase the longer you take NSAIDs WHO SHOULD NOT TAKE NSAIDS? Do talk to your doctor if you: Do not take NSAIDs if you: • have medical conditions • have had an allergic reaction to aspirin or other NSAID • are breastfeeding • are a pregnant woman late in your pregnancy • take more than one medication: show your health provider a list of all of your medicines — some may cause serious side effects when combined with NSAIDs. WHAT ARE SERIOUS SIDE EFFECTS YOU
    [Show full text]
  • Arthritis Treatment Comparison Arthritis Treatment Comparison
    ARTHRITIS TREATMENT COMPARISON ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA CHELATING AGENTS Penicillamine Cap: 250mg ✓ (Cuprimine) Penicillamine Tab: 250mg ✓ (Depen) CYCLIC POLYPEPTIDE IMMUNOSUPPRESSANTS Cyclosporine Cap: 25mg, 100mg; ✓ (Gengraf, Neoral) Sol: 100mg/mL CYCLOOXYGENASE-2 INHIBITORS Celecoxib Cap: 50mg, 100mg, ✓ ✓ ✓ ✓ (Celebrex) 200mg, 400mg DIHYDROFOLIC ACID REDUCTASE INHIBITORS Methotrexate Inj: 25mg/mL; ✓ ✓ Tab: 2.5mg Methotrexate Tab: 5mg, 7.5mg, ✓ ✓ (Trexall) 10mg, 15mg INTERLEUKIN RECEPTOR ANTAGONISTS Anakinra Inj: 100mg/0.67mL ✓ (Kineret) Tocilizumab Inj: 20mg/mL, ✓ ✓ (Actemra) 162mg/0.9mL GOLD COMPOUNDS Auranofin Cap: 3mg ✓ (Ridaura) Gold sodium thiomalate Inj: 50mg/mL ✓ ✓ (Myochrysine) HYALURONAN AND DERIVATIVES Hyaluronan Inj: 30mg/2mL ✓ (Orthovisc) Sodium hyaluronate Inj: 1% ✓ (Euflexxa) Sodium hyaluronate Inj: 10mg/mL ✓ (Hyalgan) Sodium hyaluronate Inj: 2.5mL ✓ (Supartz) HYLAN POLYMERS Hylan G-F 20 Inj: 8mg/mL ✓ (Synvisc, Synvisc One) KINASE INHIBITORS Tofacitinib Tab: 5mg ✓ (Xeljanz) MONOCLONAL ANTIBODIES Ustekinumab Inj: 45mg/0.5mL, ✓ (Stelara) 90mg/mL MONOCLONAL ANTIBODIES/CD20-BLOCKERS Rituximab Inj: 100mg/10mL, ✓ (Rituxan) 500mg/50mL (Continued) ARTHRITIS TREATMENT COMPARISON GENERIC OA of (BRAND) HOW SUPPLIED AS GA JIA JRA OA Knee PsA RA MONOCLONAL ANTIBODIES/TNF-BLOCKERS Adalimumab Inj: 20mg/0.4mL, ✓ ✓ ✓ ✓ (Humira) 40mg/0.8mL Golimumab Inj: 50mg/0.5mL, ✓ ✓ ✓ (Simponi) 100mg/mL Infliximab Inj: 100mg ✓ ✓ ✓ (Remicade) NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
    [Show full text]
  • Ketorolac Tromethamine Injection
    ! • unusual weight gain Ketorolac Tromethamine Injection, USP Rx only Table 1: Table of Approximate Average Pharmacokinetic Parameters (Mean ± SD) IV-Administration: In normal subjects (n=37), the total clearance of 30 mg IV-administered ketorolac tromethamine was Anaphylactoid Reactions 0.030 (0.017-0.051) L/h/kg. The terminal half-life was 5.6 (4.0-7.9) hours. (See Kinetics in Special Populations for use of • skin rash or blisters with fever FOR IV/IM USE (15 mg/mL and 30 mg/mL) Following Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ketorolac tromethamine. Oral† Intramuscular* Intravenous Bolus‡ IV dosing of ketorolac tromethamine in pediatric patients.) Ketorolac tromethamine should not be given to patients with the aspirin triad. This symptom complex typically occurs in • swelling of the arms and legs, hands and feet FOR IM USE ONLY (60 mg/2 mL (30 mg/mL) asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm Pharmacokinetic CLINICAL STUDIES These are not all the side effects with NSAID medicines. Talk to your healthcare provider or Parameters 10 mg 15 mg 30 mg 60 mg 15 mg 30 mg after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS – Pre-existing Asthma). Emergency WARNING (units) Adult Patients help should be sought in cases where an anaphylactoid reaction occurs. pharmacist for more information about NSAID medicines. Bioavailability 100% In a postoperative study, where all patients received morphine by a PCA device, patients treated with ketorolac tromethamine IV Cardiovascular Effects Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days (extent) in adults) management of moderately severe acute pain that requires analgesia at the opioid level.
    [Show full text]
  • 2 Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
    Drug Class Review on Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs) Final Report Update 3 Evidence Tables November 2006 Original Report Date: May 2002 Update 1 Report Date: September 2003 Update 2 Report Date: May 2004 A literature scan of this topic is done periodically The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Roger Chou, MD Mark Helfand, MD, MPH Kim Peterson, MS Tracy Dana, MLS Carol Roberts, BS Produced by Oregon Evidence-based Practice Center Oregon Health & Science University Mark Helfand, Director Copyright © 2006 by Oregon Health & Science University Portland, Oregon 97201. All rights reserved. Note: A scan of the medical literature relating to the topic is done periodically(see http://www.ohsu.edu/ohsuedu/research/policycenter/DERP/about/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Final Report Update 3 Drug Effectiveness Review Project TABLE OF CONTENTS Evidence Table 1. Systematic reviews…………………………………………………………………3 Evidence Table 2. Randomized-controlled trials………………………………………………………9 Evidence Table 3.
    [Show full text]
  • Nonsteroidal Anti-Inflammatory Drugs for Dysmenorrhoea (Review)
    Cochrane Database of Systematic Reviews Nonsteroidal anti-inflammatory drugs for dysmenorrhoea (Review) Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD001751. DOI: 10.1002/14651858.CD001751.pub3. www.cochranelibrary.com Nonsteroidal anti-inflammatory drugs for dysmenorrhoea (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 4 BACKGROUND .................................... 5 OBJECTIVES ..................................... 6 METHODS ...................................... 6 Figure1. ..................................... 8 Figure2. ..................................... 10 Figure3. ..................................... 12 RESULTS....................................... 14 Figure4. ..................................... 16 Figure5. ..................................... 18 Figure6. ..................................... 24 ADDITIONALSUMMARYOFFINDINGS . 25 DISCUSSION ..................................... 26 AUTHORS’CONCLUSIONS . 27 ACKNOWLEDGEMENTS . 27 REFERENCES ..................................... 28 CHARACTERISTICSOFSTUDIES . 40 DATAANDANALYSES. 130 Analysis 1.1. Comparison 1 NSAIDs vs placebo, Outcome 1 Pain relief dichotomous data. 136
    [Show full text]
  • Cambia (Diclofenac)
    Market Applicability Market DC GA KY MD NJ NY WA Applicable X X X X X X NA Cambia (diclofenac) Override(s) Approval Duration Prior Authorization 1 year Medications Cambia (diclofenac) packets for oral solution APPROVAL CRITERIA Requests for Cambia (diclofenac) may be approved if the following criteria is met: I. Individual has had trial (medication samples/coupons/discount cards are excluded from consideration as a trial) of and inadequate response or intolerance to two preferred generic non-steroidal anti-inflammatory drugs (NSAIDs), one of which must be a preferred generic diclofenac agent; AND II. Documentation has been provided which defines: A. The inadequate response or intolerance to two of the preferred oral NSAIDs, one of which must be a preferred generic diclofenac agent; Preferred oral NSAIDS: All generically available Ibuprofen (except Infants Advil 50mg/1.25 ML) Diclofenac Potassium Diclofenac Sodium Etodolac, Etodolac ER Fenoprofen Calcium Flurbiprofen Indomethacin Ketoprofen Ketorolac Tromethamine Meclofenamate Sodium Meloxicam Nabumetone Naproxen Sodium all generic formulations Naproxen Oxaprozin Piroxicam PAGE 1 of 2 08/19/2019 New Program Date 08/23/2017 This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply. CRX-ALL-0432-19 Market Applicability Market DC GA KY MD NJ NY WA Applicable X X X X X X NA Sulindac Tolmetin Sodium AND B. The medical reason Cambia (diclofenac) is clinically necessary. State Specific Mandates State name Date effective Mandate details (including specific bill if applicable) N/A N/A N/A Key References: 1.
    [Show full text]
  • Inflammatory Drugs (Nsaids) for People with Or at Risk of COVID-19
    Evidence review Acute use of non-steroidal anti- inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 Publication date: April 2020 This evidence review sets out the best available evidence on acute use of non- steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19. It should be read in conjunction with the evidence summary, which gives the key messages. Evidence review commissioned by NHS England Disclaimer The content of this evidence review was up-to-date on 24 March 2020. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. For details on the date the searches for evidence were conducted see the search strategy. Copyright © NICE 2020. All rights reserved. Subject to Notice of rights. ISBN: 978-1-4731-3763-9 Contents Contents ...................................................................................................... 1 Background ................................................................................................. 2 Intervention .................................................................................................. 2 Clinical problem ........................................................................................... 3 Objective ...................................................................................................... 3 Methodology ................................................................................................ 4 Summary of included studies
    [Show full text]
  • Aspirin and Other Anti-Inflammatory Drugs
    Thorax 2000;55 (Suppl 2):S3–S9 S3 Aspirin and other anti-inflammatory drugs Thorax: first published as 10.1136/thorax.55.suppl_2.S3 on 1 October 2000. Downloaded from Sir John Vane Historical introduction inhibiting COX, thereby reducing prosta- Salicylic acid, the active substance in plants glandin formation, providing a unifying expla- used for thousands of years as medicaments, nation for their therapeutic actions and their was synthesised by Kolbe in Germany in 1874. side eVects. This also firmly established certain MacLagan1 and Stricker2 showed that it was prostaglandins as important mediators of eVective in rheumatic fever. A few years later inflammatory disease (see reviews by Vane and sodium salicylate was also in use as a treatment Botting7 and Vane et al8). COX first cyclises for chronic rheumatoid arthritis and gout as arachidonic acid to form prostaglandin (PG) well as an antiseptic compound. G2 and the peroxidase part of the enzyme then Felix HoVman was a young chemist working reduces PGG2 to PGH2. at Bayer. Legend has it that his father, who was taking salicylic acid to treat his arthritis, Discovery of COX-2 complained to his son about its bitter taste. Over the next 20 years several groups postu- Felix responded by adding an acetyl group to lated the existence of isoforms of COX. Then salicylic acid to make acetylsalicylic acid. Rosen et al,9 studying COX in epithelial cells Heinrich Dreser, the Company’s head of phar- from the trachea, found an increase in activity macology, showed it to be analgesic, anti- of COX during prolonged cell culture.
    [Show full text]